# US 2026/0023073 A1 · Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0023073 A1
- Document ID: US20260023073A1
- Status: Published application
- Kind: A1
- Application number: 19/345,445
- Filed: 2025-09-30
- Published: 2026-01-22
- Earliest claimed: 2009-06-25
- Assignees: Horizon Therapeutics USA, Inc.
- Applicants: Horizon Therapeutics USA, Inc.
- Inventors: Theresa ROSARIO-JANSEN; David Erick WRIGHT
- Web page: https://patentgrep.com/patent/US20260023073A1

## CPC

- G01N 33/5308: {for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 38/44: Oxidoreductases (1)
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- C12Y 107/03003: Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 2333/90694: with oxygen as acceptor (1.7.3), e.g. uricase (1.7.3.3)
- G01N 2800/107: Crystal induced conditions; Gout
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N 2800/56: Staging of a disease; Further complications associated with the disease
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.

## Claims

### Claim at position 1

1-37. (canceled)

### Claim 38

A method of lowering the risk of an infusion reaction while treating chronic gout refractory to conventional therapy in a patient, the method comprising:
a. intravenously administering to the patient a PEGylated uricase protein every 2 or every 4 weeks;
b. measuring the serum uric acid level of the patient after each said administration; and
c. either continuing to administer the PEGylated uricase protein if the patient's serum uric acid is measured to be less than 6 mg/dl, or discontinuing administration of the PEGylated uricase protein if the patient's serum uric acid level is measured to be at least 6 mg/dl, thereby lowering the risk of an infusion reaction;
wherein the PEGylated uricase protein is selected from the group consisting of an Aspergillus flavus uricase that has been PEGylated, an Arthrobacter globiformis uricase that has been PEGylated, a Candida utilis uricase that has been PEGylated, and pegloticase; and
wherein each PEG molecule of the PEGylated uricase has a molecular weight between 1 kDa and 50 kDa.

### Claim 39 (depends on 38)

The method of claim 38, wherein the PEGylated uricase protein is a Candida utilis uricase that has been PEGylated or pegloticase.

### Claim 40 (depends on 39)

The method of claim 39, wherein each PEG molecule of the PEGylated uricase has a molecular weight between 5 kDa and 20 kDa.

### Claim 41 (depends on 40)

The method of claim 40, wherein each PEG molecule of the PEGylated uricase has a molecular weight of between 10 kDa and 12 kDa.

### Claim 42 (depends on 40)

The method of claim 40, wherein each PEG molecule of the PEGylated uricase has a molecular weight of about 10 kDa or about 20 kDa.

### Claim 43 (depends on 39)

The method of claim 39, wherein the PEGylated uricase protein is pegloticase.

### Claim 44 (depends on 39)

The method of claim 39, wherein the PEGylated uricase protein is a Candida utilis uricase that has been PEGylated.

### Claim 45 (depends on 38)

The method of claim 38 wherein the PEGylated uricase protein is an Aspergillus flavus uricase that has been PEGylated.

### Claim 46 (depends on 38)

The method of claim 38 wherein the PEGylated uricase protein is an Arthrobacter globiformis uricase that has been PEGylated.

### Claim 47 (depends on 38)

The method of claim 38, wherein the PEGylated uricase protein is administered at a dose from 8 to 12 mg.

### Claim 48 (depends on 38)

The method of claim 38, wherein the PEGylated uricase protein is administered for up to 24 weeks.

### Claim 49 (depends on 38)

The method of claim 38, wherein the serum uric acid level is measured 1 week after each administration of the PEGylated uricase protein.

### Claim 50 (depends on 39)

The method of claim 39, wherein the serum uric acid level is measured 1 week after each administration of the PEGylated uricase protein.

### Claim 51 (depends on 42)

The method of claim 42, wherein the serum uric acid level is measured 1 week after each administration of the PEGylated uricase protein.

### Claim 52 (depends on 38)

The method of claim 38, wherein the serum uric acid level is measured 2 weeks after each administration of the PEGylated uricase protein.

### Claim 53 (depends on 39)

The method of claim 39, wherein the serum uric acid level is measured 2 weeks after each administration of the PEGylated uricase protein.

### Claim 54 (depends on 42)

The method of claim 42, wherein the serum uric acid level is measured 2 weeks after each administration of the PEGylated uricase protein.

### Claim 55 (depends on 38)

The method of claim 38, wherein the serum uric acid level is measured 3 weeks after each administration of the PEGylated uricase protein.

### Claim 56 (depends on 39)

The method of claim 39, wherein the serum uric acid level is measured 3 weeks after each administration of the PEGylated uricase protein.

### Claim 57 (depends on 42)

The method of claim 42, wherein the serum uric acid level is measured 3 weeks after each administration of the PEGylated uricase protein.

### Claim 58 (depends on 38)

The method of claim 38, wherein the conventional therapy is allopurinol.

### Claim 59 (depends on 38)

The method of claim 38, wherein the PEGylated uricase protein is administered intravenously every 2 weeks.

### Claim 60 (depends on 38)

The method of claim 38, wherein the PEGylated uricase protein is administered intravenously every 4 weeks.

### Claim 61 (depends on 39)

The method of claim 39, wherein the PEGylated uricase protein is administered intravenously every 2 weeks.

### Claim 62 (depends on 39)

The method of claim 39, wherein the PEGylated uricase protein is administered intravenously every 4 weeks.

### Claim 63 (depends on 42)

The method of claim 42, wherein the PEGylated uricase protein is administered intravenously every 2 weeks.

### Claim 64 (depends on 42)

The method of claim 42, wherein the PEGylated uricase protein is administered intravenously every 4 weeks.
